Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
In contrast, earlier trials like the LEADER (liraglutide) and SUSTAIN-6 (semaglutide 1.0 mg) trial enrolled people with type 2 diabetes and high cardiovascular risk
Annualized, that's roughly $3,576$13,788/year depending on which medication and pricing tier you land on
Semaglutide the original ~14.9% average body-weight reduction at 52 weeks Targets GLP-1 (one pathway) Weekly injection Best for: first-timers, or anyone sensitive to side effects Tirzepatide the upgrade ~22.1% average body-weight reduction at 52 weeks Targets GLP-1 + GIP (two pathways) Weekly injection Best for: plateaued on semaglutide, or want stronger results Retatrutide the newest ~25.9% average body-weight reduction at 52 weeks Targets GLP-1 + GIP + glucagon (three pathways) Weekly injection Best for: want the newest science, comfortable with a compounded option Semaglutide: the original Semaglutide is a GLP-1 receptor agonist
Boutique firms : These firms specialize in one or a few practice areas, offering extensive knowledge in that niche
